It has been reported that the variants of the PDE4D (phosphodiesterase 4D) gene are associated with stroke, especially with the combination of cardio-embolic and carotid stroke in the Icelandic population, but it is still very controversial as to whether PDE4D is a susceptible gene for stroke in other populations. In the present study, we tested whether the PDE4D gene variation also confers stroke risk in a Chinese population. Our hypothesis was tested in a case-control study of a Chinese population comprising 639 stroke patients (including 253 with cerebral thrombosis, 171 with lacunar infarction and 215 with intracerebral haemorrhage) and 887 healthy controls. Three SNPs (single nucleotide polymorphisms) (rs966221, rs456009 and rs2910829) in PDE4D were chosen based on the significant association with stroke reported previously in a Western population, and these were genotyped using PCR/RFLP (restriction-fragment-length polymorphism) and confirmed by sequencing. We found that only SNP83 (rs966221) was associated with stroke. Allele C of rs966221 is a risk allele, conferring an increased risk for atherothrombotic strokes [OR (odds ratio), 1.51; 95 % CI (confidence interval), 1.09-2.10] independent of conventional risk factors. Haplotype analysis confirmed that haplotype G-C-C was associated with increased risk for atherothrombotic stroke (OR, 1.80; 95 % CI, 1.300-2.491). Our findings support that SNP83 of PDE4D is a genetic risk factor for atherothrombotic strokes in a Chinese population.
INTRODUCTION
Stroke is a major cause of mortality and disability in China. Each year, more than 2.5 million individuals suffer a stroke, 1.5 million die of stroke-related causes, and 7 million have survived a stroke, but are left permanently disabled. The reasons why there is a high incidence of stroke in this population remains unknown. Although conventional risk factors such as lipid profiles, smoking and hypertension account for a considerable part of the stroke events, most subjects with these risk factors do not develop stroke during their lifetime, suggesting that additional risk factors are at play. Family history of stroke has long been known as an independent risk factor for stroke, suggesting that genetic variations play a significant role in stroke pathogenesis. Therefore identifying culprit genetic variants may provide a predictive marker and/or novel targets for stroke prevention.
The human PDE4D (phosphodiesterase 4D) gene spans 1.5 Mb regions on chromosome 5q12 and contains 24 exons and nine splice variants. PDE4D is a cAMPspecific key signal transduction molecule in multiple tissues and cell types. In 2002, the investigators of the Iceland DeCODE study identified a locus associated with stroke on 5q12 using a genome-wide association study [1] . Subsequently, they found that PDE4D within their region of interest was associated with stroke, especially with cardiogenic and carotid stroke, in the population [2] . Following that study, the association between stroke and PDE4D has been reported in different ethnic populations with very controversial results [5] [6] [7] 9, 10] ; however, this association has not been tested in a Chinese population. In the present study, we investigated whether the reported association of ischaemic stroke with PDE4D could also be replicated in a Chinese population. Three variants were chosen in the putative promoter, intron 2 and 3 regions of PDE4D based on the strongest association with stroke in the Icelandic population [1] . The three variants are located at the 5 regulatory region of the gene, which might be involved in transcription, splicing, message stability or message transport of one or more isoforms. We investigated whether the three variants of PDE4D were associated with subtypes of ischaemic stroke and intracerebral haemorrhagic stroke.
MATERIALS AND METHODS

Subjects
This was a multicentre study for assessment of risk factors for stroke sponsored by the Ministry of Science and Technology of China. Cases and controls were recruited from the same demographic area and at the same time from November 2000 to November 2001 from four clinical centres (Xi'an, Chongqing, Beijing and Tianjin). All participants reported themselves as Han nationality. Three subtypes of stroke were included: cerebral thrombosis (atherothrombosis), lacunar infarction (lacunar) and intracerebral haemorrhagic (haemorrhage). Stroke was diagnosed by the results of strict neurological examination, CT (computed tomography) or MRI (magnetic resonance imaging), according to the International Classification of Diseases (ninth revision). The subjects comprised 253 patients with cerebral thrombosis, 171 patients with lacunar infarction and 215 patients with intracerebral haemorrhage. Controls (n = 887) were selected from inpatients with minor illness from the departments of ophthalmology, gastroenterology, otorhinolaryngology and orthopaedics, and from community-based inhabitants free of neurological diseases following the same exclusion criteria as cases. At each local community appointed, both men and women (aged 35-74 years) in the area of selection were grouped by age (5 year age range for each group), and when one case was enrolled, a control was randomly selected from the corresponding group. The residential areas of cases and controls were matched to eliminate the effect of population stratification by heterogeneity.
Exclusion criteria included TIA (transient ischaemic attack), subarachnoid haemorrhage, embolic brain infarction, brain tumours and cerebrovascular malformation, and severe systemic diseases such as collagenosis, endocrine and metabolic disease (except diabetes mellitus), inflammation, and liver, neoplastic or renal diseases.
The study protocol was approved by the review board of the Ministry of Public Health, Ministry of Science and Technology of China and the ethics committees at all of the participating hospitals. Informed consent was obtained from all individuals. All investigators were qualified to undertake the study.
Determination of biochemical variables and clinical data collection
Blood samples were collected after a 12-h overnight fast. All samples were analysed using an automatic analyser (Hitachi 7060) for serum sodium, potassium, creatinine, uric acid, BUN (blood urea nitrogen), total plasma cholesterol, TAG [triacylglycerol (triglyceride)], HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol) and blood glucose within 3 months. In addition, a complete medical history was obtained from all subjects, including family history of hypertension, diabetes mellitus and the following cardiovascular risk factors: alcohol intake, cigarette smoking, family history, weight, height, SBP (systolic blood pressure) and DBP (diastolic blood pressure). Hypertension was defined, according to WHO (World Health Organization) criteria, as SBP 140 mmHg and/or DBP 90 mmHg on an average of three measurements or by current antihypertensive drugs. Diabetes mellitus was diagnosed when the subject had a fasting glucose 7.8 mmol/l, 11.1 mmol/l at 2 h after oral glucose challenge, or both.
Genotyping
Peripheral blood (10 ml) was collected into tubes containing trisodium citrate (at a final concentration of 0.026 mol/l), centrifuged at 3000 g for 10 min at room temperature (25
• C), and plasma and 'buffy coat' were separated and stored in 1.5 ml EP tubes at − 70
• C. All assays were performed in duplicate. DNA was extracted from 'buffy coat' as described previously [3] , and stored at − 70
• C before use. The previous study by Gretarsdottir et al. [1] identified 260 novel variants and numbered them numerically. To avoid confusion and to aid replication, we maintained this nomenclature throughout. The SNP (single nucleotide polymorphism) 32, SNP83 and SNP87 polymorphisms genotypes of PDE4D were detected by PCR/RFLP (restriction-fragment-length polymorphism). The sequence containing the SNP32 polymorphism was amplified by PCR with the following primers: 5 -GACATAGCAAGAACCTG-AC-3 and 5 -GGTATCATAGTGGCTGTAGT-3 . The resultant PCR products of 159 bp were digested with PvuII (New England Biolabs). Two fragments of 96 bp and 63 bp were observed for the G allele on a 4 % (w/v) agarose gel, whereas only a 159 bp band was seen for the A allele. The sequences containing the SNP83 polymorphism were amplified by PCR with the sense primer 5 -AGGTTGTTTTATTAAGAGATGC-3 and antisense primer 5 -TCTAAAGTTCTCAAAAGTG-TTC-3 . The resulting 282 bp fragment was digested with HpyCH4IV (New England Biolabs). Two fragments of 111 bp and 171 bp were observed for the C allele on a 2 % (w/v) agarose gel, whereas only a 282 bp band was seen for the T allele. The sequence containing the SNP87 polymorphism was amplified by PCR with the following primers: 5 -GTATGAAGACACCTGAAAGAT-3 and 5 -GATGAGGAAGAATAATGGAT-3 . The resultant PCR products of 195 bp were digested with SspI (New England Biolabs). Two fragments of 158 bp and 37 bp were observed for the T allele on a 4 % (w/v) agarose gel, whereas only a 195 bp band was seen for the C allele. The detected variation was confirmed by sequencing 200 random samples with an ABI Prism 3730 Genetic Analyser (PE Applied Biosystems) [4] , and the reproducibility was 100 %.
Statistical analysis
Results are expressed as means + − S.D. A one-way ANOVA test was used for comparison of quantitative variables, including age, BMI (body mass index), SBP, DBP, glucose, HDL-C, LDL-C and total plasma cholesterol. A χ 2 test was used to test categorical variables, the Hardy-Weinberg equilibrium of the polymorphisms and genotype/allele frequencies. Association of the SNP32, SNP83 and SNP87 polymorphisms with stroke was analysed by multivariable logistic regression, adjusted for age, gender, BMI, SBP, DBP, smoking, alcohol consumption, glucose, HDL-C, LDL-C, total plasma cholesterol and TAG. The association was expressed as an OR (odds ratio). A value of P < 0.05 was considered significant. Statistical analysis was performed with a SPSS 13.0 package. A SHEsis software platform was used to analyse pairwise LD (linkage disequilibrium), and haplotype association of the polymorphisms in the case-control study. The threshold value for haplotype frequency that was included in the analysis was set at 3 %. A probability value 0.017 (0.05/3) was considered statistically significant after Bonferroni correction in the single-locus analysis. In the haplotype analysis and multilocus LD tests, the probability value was also corrected according to the number of tests performed.
RESULTS
Characteristics of the subjects
Clinical characteristics of the subjects in the present study are shown in Table 1 . Stroke patients had a higher prevalence of conventional vascular risk factors, including history of hypertension and diabetes mellitus, significantly higher levels of SBP, DBP, total plasma cholesterol and glucose, and lower levels of HDL-C, whereas total TAG and LDL-C levels in patients were surprisingly lower in stroke patients than in controls.
Variant SNP83 (rs966221) was associated with stroke
The distribution of T/T, C/T and C/C genotypes of SNP83 are shown in Table 2 . They were in agreement with the Hardy-Weinberg equilibrium in both cases and controls. The estimated risk of patients with atherothrombotic stroke with the C/T genotype (one copy of the risk allele C) was significantly higher than those with the T/T genotype (no copy of the risk allele C), but was comparable with those with the C/C genotype, indicating a dominant effect of the at-risk allele C. We used the dominant model to analyse the association between the C allele and stroke. The frequency of the genotype C/C + C/T was significantly higher in patients with atherothrombotic stroke than in controls (42.3 % compared with 32.3 %, P < 0.01). The association remained after adjustment for age, gender and other conventional risk factors with multiple logistic regression analysis [OR, 1.51; 95 % CI (confidence interval), 1.09-2.10], whereas no difference was identified in the frequencies of C/C + C/T between the other two stroke subtypes (lacunar infarct stroke or intracerebral haemorrhagic stroke) and controls.
SNP32 (rs456009) and SNP87 (rs2910829) polymorphisms
The distributions of SNP32 and SNP87 genotype frequencies are summarized in Table 3 . They were in agreement with Hardy-Weinberg equilibrium in both patients and controls. No statistically significant differences in SNP32 and SNP87 genotype frequencies were found by χ 2 test in patients and controls (χ 2 = 2.71, P = 0.25; χ 2 = 2.71, P = 0.90). No association between the two SNPs and stroke was found in patients or controls.
LD analysis
LD was performed between the three SNPs by using the standard definition of D and r 2 . We found that the three SNPs were not in LD with D = 0.026, r 2 = 0.001 (between SNP32 and SNP83); D = 0.123, r 2 = 0.013 (between SNP83 and SNP87); and D = 0.02, r 2 = 0.001 (between SNP32 and SNP87). We also constructed haplotypes using SNP32, SNP83 and Table 2 Association of SNP83 in PDE4D with stroke Crude ORs and 95 % CIs were calculated with 2 × 2 cross tabulation, and adjusted ORs and 95 % CIs were calculated with the use of multivariable logistic regression analyses after adjusting for age, gender, BMI, SBP, DBP, glucose, HDL-C, LDL-C, TAG and total plasma cholesterol. * P < 0.05 and * * P < 0.01 compared with controls (using a χ 2 test). SNP87 and tested the haplotype association with stroke. Seven major haplotypes (each frequency > 3 %) were observed in controls and stroke patients. The distribution of the haplotypes showed a significant difference between the patients with atherothrombotic stroke and controls. The frequency of the G-C-C haplotype was significantly higher in the patients with atherothrombotic stroke than in controls (see Supplementary Table S1 at http://www.clinsci.org/cs/116/ cs1160335add.htm). The haplotype G-C-C was found to be significantly associated with an increased risk of atherothrombotic stroke (OR 1.80; 95 % CI, 1.300-2.491; Pearson's P = 0.000345) ( Table 4) . No significant association was observed between the haplotypes and lacunar infarction or intracerebral haemorrhagic stroke.
DISCUSSION
The present study confirmed that SNP83 of PDE4D was associated with stroke in a Chinese population. The variant of SNP83 conferred a 1.51-fold increased risk of atherothrombotic stroke. The G-C-C haplotype was also found to be associated with an increased risk of atherothrombotic stroke, but not for lacunar infarction and intracerebral haemorrhagic stroke, suggesting that the variant of SNP83 was a genetic risk factor for atherothrombotic stroke, but not for lacunar infarction and intracerebral haemorrhagic stroke. This finding is consistent with the results reported by the DeCODE group, in which the stroke association was found with SNPs, microsatellite markers and haplotypes in an Icelandic population [1, 2] . Subsequently, some, but not all, studies confirmed the association [5] [6] [7] [8] [9] [10] [11] . Several reasons might explain the conflicting results among these studies. First, the frequency of genotypes, alleles, haplotypes and LD pattern may differ among different ethnic groups. Secondly, the prevalence and clinical features of stroke are different in different ethnic populations. Thirdly is the methodological limitation. In case-control studies, including the present study, cases are only from patients who are survivors of stroke, which might neglect the real role of candidate modifiers [12] . PDE4D is a member of a large super-family of cyclic nucleotide PDEs, which selectively degrade the secondmessenger cAMP. PDE4D is expressed in cells types related to atherosclerosis, including vascular smooth muscle cells, endothelial cells and macrophages [13] [14] [15] . cAMP is also a central signal transduction molecule in different cell types. Low levels of cAMP enhance vascular smooth muscle cell migration and proliferation [16] , whereas elevated levels of cAMP reduce neointimal lesion formation and inhibit proliferation of smooth muscle cells after arterial injury [17] . These mechanisms may be involved in the pathogenesis of atherosclerosis. The present study also suggested that PDE4D variants were only associated with atherothrombotic stroke, which is caused by large-artery atherosclerosis, not with lacunar infarction stroke caused by lipohyalinosis or microatheromata with thrombosis of the vascular lumen (≈ 30-100 μm) and intracerebral haemorrhagic stroke due to microaneurysms in intracerebral arteries (whether this is the main cause is still in debate). Moreover, PDE4 enzymes predominate cAMP metabolism in inflammatory cells, which accounts for at least 80 % of PDE activity in inflammatory cells [18, 19] . PDE4D enzyme activity could play an important role in stroke risk through its effects on inflammation and plaque stability. Overexpression of PDE4D can decrease the second messenger cAMP activity and increase vascular smooth muscle cell migration, inflammation and atherosclerotic plaque instability, a risk for large-artery atherosclerosis [20, 21] . In addition, the expression of multiple PDE4D isforms is lower in patients with ischaemic stroke than in controls [2] . This also implies that the gene may be involved in the pathogenesis of stroke.
The present study is a multicentre case-controlled study, which avoids selection bias of patients. In the present study, the various subtypes of stroke patients were selected based on strict neurological examination, CT or MRI according to the International Classification of Diseases (ninth revision); however, some limitations must be considered. The present study focused on the variants at the 5 end of the gene, which might miss the possible association of PDE4D variants with stroke in other regions. Therefore our results need to be confirmed in other cohorts.
In conclusion, our findings provide support that SNP83 of PDE4D is a genetic risk factor for atherothrombotic strokes in a Chinese population. 
